small molecule

GEMTESA

VIBEGRON

Loss of exclusivityJuly 2042latest FDA-listed patent expiry

CompanySumitomo Pharma America →See this company's full patent-cliff portfolio

Drug detail

Brand name	GEMTESA
Active ingredient	VIBEGRON
Strength	75MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	December 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12357636	July 2042	use U-4219
12102638	March 2040	use U-3045
8247415	December 2034	substance, product
12180219	March 2034	substance, product
8653260	April 2029	substance

Regulatory exclusivity

Code	Expires
I-955	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Sumitomo Pharma America